Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone

doi:10.1084/jem.183.3.927

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Bianchi, M.
	Articles by Tracey, K. J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Bianchi, M.
	Articles by Tracey, K. J.


Social Bookmarking

	What's this?

ARTICLES

Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone

M Bianchi, O Bloom, T Raabe, PS Cohen, J Chesney, B Sherry, H Schmidtmayerova, T Calandra, X Zhang, M Bukrinsky, P Ulrich, A Cerami and KJ Tracey
Department of Surgery, North Shore University Hospital, Manhasset, New York 11030, USA.

An overproduction of proinflammatory cytokines by activated macrophages/monocytes mediates the injurious sequelae of inflammation, septic shock, tissue injury, and cachexia. We recently synthesized a tetravalent guanylhydrazone compound (CNI-1493) that inhibits cytokine- inducible arginine transport and nitric oxide (NO) production in macrophages, and protects mice against lethal endotoxemia and carrageenan-induced inflammation. During these investigations we noticed that CNI-1493 effectively prevented lipopolysaccharide (LPS)- induced NO production, even when added in concentrations 10-fold less than required to competitively inhibit L-arginine uptake, suggesting that the suppressive effects of this guanylhydrazone compound might extend to other LPS-induced responses. Here, we report that CNI-1493 suppressed the LPS-stimulated production of proinflammatory cytokines (tumor necrosis factor [TNF], interleukins 1beta and 6, macrophage inflammatory proteins 1alpha and 1beta) from human peripheral blood mononuclear cells. Cytokine suppression was specific, in that CNI-1493 did not inhibit either the constitutive synthesis of transforming growth factor beta or the upregulation of major histocompatibility complex class II by interferon gamma (IFN-gamma). In contrast to the macrophage suppressive actions of dexamethasone, which are overridden in the presence of IFN-gamma, CNI-1493 retained its suppressive effects even in the presence of IFN-gamma. The mechanism of cytokine- suppressive action by CNI-1493 was independent of extracellular L- arginine content and NO production and is not restricted to induction by LPS. As a selective inhibitor of macrophage activation that prevents TNF production, this tetravalent guanylhydrazone could be useful in the development of cytokine-suppressive agents for the treatment of diseases mediated by overproduction of cytokines.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Bacher, M., Dodel, R., Aljabari, B., Keyvani, K., Marambaud, P., Kayed, R., Glabe, C., Goertz, N., Hoppmann, A., Sachser, N., Klotsche, J., Schnell, S., Lewejohann, L., Al-Abed, Y. (2008). CNI-1493 inhibits A{beta} production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease. J. Exp. Med. 205: 1593-1599 [Abstract] [Full Text]
Oke, S. L., Tracey, K. J. (2008). From CNI-1493 to the immunological homunculus: physiology of the inflammatory reflex. J. Leukoc. Biol. 83: 512-517 [Abstract] [Full Text]
Kociok, N., Radetzky, S., Krohne, T. U., Gavranic, C., Joussen, A. M. (2006). Pathological but Not Physiological Retinal Neovascularization Is Altered in TNF-Rp55-Receptor-Deficient Mice. IOVS 47: 5057-5065 [Abstract] [Full Text]
Zamora, R., Grishin, A., Wong, C., Boyle, P., Wang, J., Hackam, D., Upperman, J. S., Tracey, K. J., Ford, H. R. (2005). High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G643-G652 [Abstract] [Full Text]
Lowenberg, M., Verhaar, A., van den Blink, B., ten Kate, F., van Deventer, S., Peppelenbosch, M., Hommes, D. (2005). Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn's Disease. J. Immunol. 175: 2293-2300 [Abstract] [Full Text]
Takeda, R., Suzuki, E., Satonaka, H., Oba, S., Nishimatsu, H., Omata, M., Fujita, T., Nagai, R., Hirata, Y. (2005). Blockade of Endogenous Cytokines Mitigates Neointimal Formation in Obese Zucker Rats. Circulation 111: 1398-1406 [Abstract] [Full Text]
Gardiner, T. A., Gibson, D. S., de Gooyer, T. E., de la Cruz, V. F., McDonald, D. M., Stitt, A. W. (2005). Inhibition of Tumor Necrosis Factor-{alpha} Improves Physiological Angiogenesis and Reduces Pathological Neovascularization in Ischemic Retinopathy. Am. J. Pathol. 166: 637-644 [Abstract] [Full Text]
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., Czura, C. J., Wang, H., Roth, J., Warren, H. S., Fink, M. P., Fenton, M. J., Andersson, U., Tracey, K. J. (2004). Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101: 296-301 [Abstract] [Full Text]
Czura, C. J., Friedman, S. G., Tracey, K. J. (2003). Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. Innate Immunity 9: 409-413 [Abstract]
Foxwell, B, Andreakos, E, Brennan, F, Feldmann, M, Smith, C, Conron, M (2003). Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Ann Rheum Dis 62: ii90-93 [Full Text]
Yuksel, M., Okajima, K., Uchiba, M., Okabe, H. (2003). Gabexate Mesilate, a Synthetic Protease Inhibitor, Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-alpha Production by Inhibiting Activation of Both Nuclear Factor-kappa B and Activator Protein-1 in Human Monocytes. J. Pharmacol. Exp. Ther. 305: 298-305 [Abstract] [Full Text]
Hommes, D W, Peppelenbosch, M P, van Deventer, S J H (2003). Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52: 144-151 [Abstract] [Full Text]
Granert, C., Abdalla, H., Lindquist, L., Diab, A., Bakhiet, M., Tracey, K. J., Andersson, J. (2000). Suppression of Macrophage Activation with CNI-1493 Increases Survival in Infant Rats with Systemic Haemophilus influenzae Infection. Infect. Immun. 68: 5329-5334 [Abstract] [Full Text]
Lali, F. V., Hunt, A. E., Turner, S. J., Foxwell, B. M. J. (2000). The Pyridinyl Imidazole Inhibitor SB203580 Blocks Phosphoinositide-dependent Protein Kinase Activity, Protein Kinase B Phosphorylation, and Retinoblastoma Hyperphosphorylation in Interleukin-2-stimulated T Cells Independently of p38 Mitogen-activated Protein Kinase. J. Biol. Chem. 275: 7395-7402 [Abstract] [Full Text]
Hunt, A. E., Lali, F. V., Lord, J. D., Nelson, B. H., Miyazaki, T., Tracey, K. J., Foxwell, B. M.�J. (1999). Role of Interleukin (IL)-2 Receptor beta -Chain Subdomains and Shc in p38 Mitogen-activated Protein (MAP) Kinase and p54 MAP Kinase (Stress-activated Protein Kinase/c-Jun N-terminal Kinase) Activation. IL-2-DRIVEN PROLIFERATION IS INDEPENDENT OF p38 AND p54 MAP KINASE ACTIVATION. J. Biol. Chem. 274: 7591-7597 [Abstract] [Full Text]
Zybarth, G., Reiling, N., Schmidtmayerova, H., Sherry, B., Bukrinsky, M. (1999). Activation-Induced Resistance of Human Macrophages to HIV-1 Infection In Vitro. J. Immunol. 162: 400-406 [Abstract] [Full Text]
Wang, H., Zhang, M., Bianchi, M., Sherry, B., Sama, A., Tracey, K. J. (1998). Fetuin (alpha 2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc. Natl. Acad. Sci. USA 95: 14429-14434 [Abstract] [Full Text]
Martiney, J. A., Rajan, A. J., Charles, P. C., Cerami, A., Ulrich, P. C., Macphail, S., Tracey, K. J., Brosnan, C. F. (1998). Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by CNI-1493, a Macrophage-Deactivating Agent. J. Immunol. 160: 5588-5595 [Abstract] [Full Text]
Kemeny, M. M., Botchkina, G. I., Ochani, M., Bianchi, M., Urmacher, C., Tracey, K. J. (1998). The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Proc. Natl. Acad. Sci. USA 95: 4561-4566 [Abstract] [Full Text]
Villa, P., Meazza, C., Sironi, M., Bianchi, M., Ulrich, P., Botchkina, G., Tracey, K.J., Ghezzi, P. (1997). Protection against lethal polymicrobial sepsis by CNI-1493, an inhibitor of pro-inflammatory cytokine synthesis. Innate Immunity 4: 197-204 [Abstract]